publication date: Apr. 24, 2015

Baselga Becomes AACR President. Two SU2C Dream Teams Launched, And Multiple Award Winners Named

 

José Baselga was inaugurated as president of the American Association for Cancer Research for 2015-2016, during the association’s annual meeting in Philadelphia.

Baselga is physician-in-chief and chief medical officer at Memorial Sloan Kettering Cancer Center in New York.

“It is an honor to serve as president of the AACR,” Baselga said. “We are currently in the midst of a revolution in cancer research, where new technologies and therapies are being developed at a record pace. The AACR is uniquely positioned to advance the promise of precision medicine initiatives. As president, I am eager to work with the AACR community as a whole to integrate basic and clinical research, improve access to clinical trials, coordinate our regulatory policies, and increase our ability to collaborate on the many breakthroughs occurring in cancer prevention, detection, and treatment.”

Baselga helped pioneer treatments for women with HER2-positive breast cancer. He conducted the initial clinical trial that demonstrated that patients with advanced HER2-positive breast cancer benefited from treatment with the anti-HER2 monoclonal antibody trastuzumab. His most recent focus in the laboratory and clinic is the identification of mechanisms of resistance to anti-HER2 agents and the clinical development of novel agents—including PI3-kinase inhibitors and antiestrogen therapies.

Baselga has been actively involved in the AACR for more than 20 years. Together with Lewis Cantley, Baselga is a founding editor-in-chief of Cancer Discovery. He has served as a member of the board of directors (2009-2012), and member of the editorial boards of Clinical Cancer Research … Continue reading 41-16 Baselga Becomes AACR President. Two SU2C Dream Teams Launched, And Multiple Award Winners Named

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.